摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2S,10S,10aR)-9-acetoxymethyl-10-benzoyloxy-5-oxo-1,2,3,5,10,10a-hexahydropyrrolo[1,2-b]isoquinolin-2-yl (4'S,5'R)-3'-benzoyl-2'-(4-methoxy-phenyl)-4'-phenyloxazolidine-5'-carboxylate | 1255794-65-0

分子结构分类

中文名称
——
中文别名
——
英文名称
(2S,10S,10aR)-9-acetoxymethyl-10-benzoyloxy-5-oxo-1,2,3,5,10,10a-hexahydropyrrolo[1,2-b]isoquinolin-2-yl (4'S,5'R)-3'-benzoyl-2'-(4-methoxy-phenyl)-4'-phenyloxazolidine-5'-carboxylate
英文别名
——
(2S,10S,10aR)-9-acetoxymethyl-10-benzoyloxy-5-oxo-1,2,3,5,10,10a-hexahydropyrrolo[1,2-b]isoquinolin-2-yl (4'S,5'R)-3'-benzoyl-2'-(4-methoxy-phenyl)-4'-phenyloxazolidine-5'-carboxylate化学式
CAS
1255794-65-0
化学式
C46H40N2O10
mdl
——
分子量
780.831
InChiKey
YBRZSUGNENEKRJ-KJZQGLAGSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    6.78
  • 重原子数:
    58.0
  • 可旋转键数:
    10.0
  • 环数:
    8.0
  • sp3杂化的碳原子比例:
    0.24
  • 拓扑面积:
    137.98
  • 氢给体数:
    0.0
  • 氢受体数:
    10.0

反应信息

  • 作为反应物:
    描述:
    (2S,10S,10aR)-9-acetoxymethyl-10-benzoyloxy-5-oxo-1,2,3,5,10,10a-hexahydropyrrolo[1,2-b]isoquinolin-2-yl (4'S,5'R)-3'-benzoyl-2'-(4-methoxy-phenyl)-4'-phenyloxazolidine-5'-carboxylate对甲苯磺酸 作用下, 以 甲醇 为溶剂, 反应 10.0h, 以75%的产率得到(2S,10S,10aR)-9-acetoxymethyl-10-benzoyloxy-5-oxo-1,2,3,5,10,10a-hexahydropyrrolo[1,2-b]isoquinolin-2-yl (2'R,3'S)-3'-benzoylamino-2'-hydroxy-3'-phenylpropanoate
    参考文献:
    名称:
    Design and synthesis of de novo cytotoxic alkaloids by mimicking the bioactive conformation of paclitaxel
    摘要:
    Novel paclitaxel-mimicking alkaloids were designed and synthesized based on a bioactive conformation of paclitaxel, that is, REDOR-Taxol. The alkaloid 2 bearing a 5-7-6 tricyclic scaffold mimics REDOR-Taxol best among the compounds designed and was found to be the most potent compound against several drug-sensitive and drug-resistant human cancer cell lines. MD simulation study on the paclitaxel mimics 1 and 2 as well as REDOR-Taxol bound to the 1JFF tubulin structure was quite informative to evaluate the level of mimicking. The MD simulation study clearly distinguishes the 5-6-6 and 5-7-6 tricyclic scaffolds, and also shows substantial difference in the conformational stability of the tubulin-bound structures between 2 and REDOR-Taxol. The latter may account for the large difference in potency, and provides critical information for possible improvement in the future design of paclitaxel mimics. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2010.07.069
  • 作为产物:
    描述:
    (2S,10S,10aR)-9-acetoxymethyl-10-benzoyloxy-2-hydroxyl-1,2,3,5,10,10a-hexahydropyrrolo[1,2-b]isoquinolin-5-one紫杉醇侧链4-二甲氨基吡啶盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 作用下, 以 二氯甲烷 为溶剂, 以82%的产率得到(2S,10S,10aR)-9-acetoxymethyl-10-benzoyloxy-5-oxo-1,2,3,5,10,10a-hexahydropyrrolo[1,2-b]isoquinolin-2-yl (4'S,5'R)-3'-benzoyl-2'-(4-methoxy-phenyl)-4'-phenyloxazolidine-5'-carboxylate
    参考文献:
    名称:
    Design and synthesis of de novo cytotoxic alkaloids by mimicking the bioactive conformation of paclitaxel
    摘要:
    Novel paclitaxel-mimicking alkaloids were designed and synthesized based on a bioactive conformation of paclitaxel, that is, REDOR-Taxol. The alkaloid 2 bearing a 5-7-6 tricyclic scaffold mimics REDOR-Taxol best among the compounds designed and was found to be the most potent compound against several drug-sensitive and drug-resistant human cancer cell lines. MD simulation study on the paclitaxel mimics 1 and 2 as well as REDOR-Taxol bound to the 1JFF tubulin structure was quite informative to evaluate the level of mimicking. The MD simulation study clearly distinguishes the 5-6-6 and 5-7-6 tricyclic scaffolds, and also shows substantial difference in the conformational stability of the tubulin-bound structures between 2 and REDOR-Taxol. The latter may account for the large difference in potency, and provides critical information for possible improvement in the future design of paclitaxel mimics. (C) 2010 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmc.2010.07.069
点击查看最新优质反应信息

同类化合物

()-2-(5-甲基-2-氧代苯并呋喃-3(2)-亚乙基)乙酸乙酯 (甲基3-(二甲基氨基)-2-苯基-2H-azirene-2-羧酸乙酯) (反式)-4-壬烯醛 (双(2,2,2-三氯乙基)) (乙腈)二氯镍(II) (乙基N-(1H-吲唑-3-基羰基)ethanehydrazonoate) (βS)-β-氨基-4-(4-羟基苯氧基)-3,5-二碘苯甲丙醇 (±)17,18-二HETE (±)-辛酰肉碱氯化物 (±)-盐酸氯吡格雷 (±)-丙酰肉碱氯化物 (s)-2,3-二羟基丙酸甲酯 (d(CH2)51,Tyr(Me)2,Arg8)-血管加压素 ([2-(萘-2-基)-4-氧代-4H-色烯-8-基]乙酸) ([1-(甲氧基甲基)-1H-1,2,4-三唑-5-基](苯基)甲酮) (Z)-5-辛烯甲酯 (Z)-4-辛烯醛 (Z)-4-辛烯酸 (Z)-3-[[[2,4-二甲基-3-(乙氧羰基)吡咯-5-基]亚甲基]吲哚-2--2- (S,S)-邻甲苯基-DIPAMP (S)-(-)-7'-〔4(S)-(苄基)恶唑-2-基]-7-二(3,5-二-叔丁基苯基)膦基-2,2',3,3'-四氢-1,1-螺二氢茚 (S)-(-)-5'-苄氧基苯基卡维地洛 (S)-(-)-2-(α-(叔丁基)甲胺)-1H-苯并咪唑 (S)-(-)-2-(α-甲基甲胺)-1H-苯并咪唑 (S)-(+)-α-氨基-4-羧基-2-甲基苯乙酸 (S)-(+)-5,5'',6,6'',7,7'',8,8''-八氢-3,3''-二叔丁基-1,1''-二-2-萘酚,双钾盐 (S)-阿拉考特盐酸盐 (S)-赖诺普利-d5钠 (S)-盐酸沙丁胺醇 (S)-溴烯醇内酯 (S)-氨氯地平-d4 (S)-氨基甲酸酯β-D-O-葡糖醛酸 (S)-8-氟苯并二氢吡喃-4-胺 (S)-7,7-双[(4S)-(苯基)恶唑-2-基)]-2,2,3,3-四氢-1,1-螺双茚满 (S)-4-(叔丁基)-2-(喹啉-2-基)-4,5-二氢噁唑 (S)-4-氯-1,2-环氧丁烷 (S)-3-(((2,2-二氟-1-羟基-7-(甲基磺酰基)-2,3-二氢-1H-茚满-4-基)氧基)-5-氟苄腈 (S)-3-(叔丁基)-4-(2,6-二甲氧基苯基)-2,3-二氢苯并[d][1,3]氧磷杂环戊二烯 (S)-3-(2-(二氟甲基)吡啶-4-基)-7-氟-3-(3-(嘧啶-5-基)苯基)-3H-异吲哚-1-胺 (S)-2-(环丁基氨基)-N-(3-(3,4-二氢异喹啉-2(1H)-基)-2-羟丙基)异烟酰胺 (S)-2-氨基-5-氧代己酸,氢溴酸盐 (S)-2-[[[(1R,2R)-2-[[[3,5-双(叔丁基)-2-羟基苯基]亚甲基]氨基]环己基]硫脲基]-N-苄基-N,3,3-三甲基丁酰胺 (S)-2-[3-[(1R,2R)-2-(二丙基氨基)环己基]硫脲基]-N-异丙基-3,3-二甲基丁酰胺 (S)-2-N-Fmoc-氨基甲基吡咯烷盐酸盐 (S)-2,2'-双[双(3,5-三氟甲基苯基)膦基]-4,4',6,6'-四甲氧基联苯 (S)-1-(4-氨基氧基乙酰胺基苄基)乙二胺四乙酸 (S)-1-[N-[3-苯基-1-[(苯基甲氧基)羰基]丙基]-L-丙氨酰基]-L-脯氨酸 (S)-1-[3,5-双(三氟甲基)苯基]-3-[1-(二甲基氨基)-3-甲基丁烷-2-基]硫脲 (SP-4-1)-二氯双(喹啉)-钯 (SP-4-1)-二氯双(1-苯基-1H-咪唑-κN3)-钯